- Home
- MCR vs IMMP Comparison
MCR vs IMMP Comparison
Compare MCR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- IMMP
- Stock Information
- Founded
- MCR 1989
- IMMP 1987
- Country
- MCR United States
- IMMP Australia
- Employees
- MCR N/A
- IMMP N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- IMMP Health Care
- Exchange
- MCR Nasdaq
- IMMP Nasdaq
- Market Cap
- MCR 250.1M
- IMMP 211.1M
- IPO Year
- MCR N/A
- IMMP N/A
- Fundamental
- Price
- MCR $6.26
- IMMP $1.89
- Analyst Decision
- MCR
- IMMP Buy
- Analyst Count
- MCR 0
- IMMP 2
- Target Price
- MCR N/A
- IMMP $8.50
- AVG Volume (30 Days)
- MCR 66.7K
- IMMP 659.8K
- Earning Date
- MCR 01-01-0001
- IMMP 05-23-2025
- Dividend Yield
- MCR 8.52%
- IMMP N/A
- EPS Growth
- MCR N/A
- IMMP N/A
- EPS
- MCR 0.38
- IMMP N/A
- Revenue
- MCR N/A
- IMMP $3,019,249.00
- Revenue This Year
- MCR N/A
- IMMP $50.37
- Revenue Next Year
- MCR N/A
- IMMP N/A
- P/E Ratio
- MCR $16.61
- IMMP N/A
- Revenue Growth
- MCR N/A
- IMMP 24.11
- 52 Week Low
- MCR $5.63
- IMMP $1.32
- 52 Week High
- MCR $6.70
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- MCR 57.62
- IMMP 54.39
- Support Level
- MCR $6.17
- IMMP $1.78
- Resistance Level
- MCR $6.36
- IMMP $2.71
- Average True Range (ATR)
- MCR 0.06
- IMMP 0.17
- MACD
- MCR 0.02
- IMMP 0.02
- Stochastic Oscillator
- MCR 65.00
- IMMP 25.45
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.